Q.01

What does FDA CBER regulate?

FDA's Center for Biologics Evaluation and Research (CBER) regulates biological products for human use under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act. Its products include vaccines, blood and blood products, cellular and gene therapies, tissues, allergenics, live biotherapeutic products and xenotransplantation products. It also regulates some devices and a small number of drugs that are tied to its biologics.

Approach: I used FDA's official CBER pages: the center overview, "Biologics Regulated Products" and "CBER Product Jurisdiction." Our datasets list CBER approvals and licensed biologics, but they don't describe the center's remit, so FDA's own pages are the source here.

Mission: CBER's stated mission is to "protect and advance the public health by ensuring that biological products are safe and effective and available to those who need them." It also gives the public information on how to use these products safely.

Product scope, per FDA's jurisdiction page:

  • Biologics: allergenics, blood and blood products, cellular and gene therapies, tissue and tissue-based products, vaccines, live biotherapeutic products and xenotransplantation products.
  • Devices: certain devices, including selected in vitro diagnostics and devices that make biologics at the point of care.
  • Drugs: a limited number of drug products linked to blood banking or cellular therapies.

How the review work is split among CBER's three review offices:

OfficeProducts
Office of Vaccines Research and Review (OVRR)Allergenic products, vaccines against infectious diseases, probiotic therapies
Office of Therapeutic Products (OTP)Cell, tissue and gene therapies; therapeutic vaccines for non-infectious diseases; plasma derivatives
Office of Blood Research and Review (OBRR)Blood products for transfusion, donor screening assays, retroviral diagnostics

The "Biologics Regulated Products" page also lists "Biologics Products & Establishments" as a separate category.

Unclear jurisdiction: CBER's Product Jurisdiction Officer answers classification questions informally. Formal designation goes through FDA's Office of Combination Products using a Request for Designation. The jurisdiction page doesn't cover therapeutic biologics transferred to FDA's drug center (CDER) or the intercenter agreements, so I've left those out.

Sources:

Q.02

How is CBER different from CDER?

CDER (the Center for Drug Evaluation and Research) regulates drugs: prescription, over-the-counter and generic drugs, plus therapeutic biologics and biosimilars. CBER regulates the "living" or blood-derived biologics: vaccines, blood and plasma products, cell and gene therapies, tissues and allergenics. Biologics are split between them. On June 30, 2003, FDA moved some therapeutic biological products, such as monoclonal antibodies and therapeutic proteins, from CBER to CDER, so both centers now license biologics under BLAs.

Approach: I checked the center assignments in FDA's Purple Book of licensed biologics and read FDA's pages on CDER and on the 2003 transfer. FDA's pages are the source for each center's remit, since the datasets record only which center handles each product.

Side-by-side

CDERCBER
Mission (FDA wording)Ensuring "safe and effective drugs are available to improve the health of people in the United States""Protect and advance the public health by ensuring that biological products are safe and effective and available to those who need them" (from the CBER overview page cited in our previous answer)
Core productsPrescription, OTC and generic drugs; therapeutic biologics and biosimilars. Its "drug" scope also covers fluoride toothpaste, antiperspirants, dandruff shampoos and sunscreensVaccines, blood and blood products, cellular and gene therapies, tissues, allergenics, live biotherapeutics, xenotransplantation products; some devices and a few drugs tied to blood banking or cell therapy
Biologics it holdsCategories transferred in 2003: monoclonal antibodies for in vivo use; therapeutic proteins such as cytokines, enzymes and novel proteins (not vaccines or blood products); protein or peptide immunomodulators; growth factors and cytokines that alter cell productionCategories that stayed: cellular products (human, bacterial or animal cells), gene therapy, vaccines and vaccine-associated products, allergenic extracts, blood, blood components and plasma-derived products, and human cells, tissues, and cellular and tissue-based products (HCT/Ps)

How the split shows up in the Purple Book: The Purple Book lists 1,082 currently licensed product entries under CDER and 932 under CBER. A few examples:

  • CDER: monoclonal antibodies and protein therapeutics, such as Zynyz (retifanlimab-dlwr) [1], Zynlonta (loncastuximab tesirine-lpyl) [2] and Zymfentra (infliximab-dyyb) [3].
  • CBER: gene and cell therapies and vaccines, such as Zynteglo (betibeglogene autotemcel) [4], Zolgensma (onasemnogene abeparvovec-xioi) [5], Zevaskyn (prademagene zamikeracel) [6] and Zostavax (Zoster Vaccine Live) [7].

Other practical differences:

  • Application types: CDER handles NDAs and ANDAs for drugs as well as BLAs for its biologics. CBER works mainly through BLAs, along with device submissions for the devices it regulates.
  • Combination products: these go to a center based on their "primary mode of action," under section 503(g) of the FD&C Act (21 U.S.C. § 353(g)). If jurisdiction is unclear, a Request for Designation goes to FDA's Office of Combination Products.

Sources:

Q.03

How does CBER regulate human tissues?

CBER regulates human tissues as human cells, tissues, and cellular and tissue-based products (HCT/Ps) under 21 CFR Parts 1270 and 1271. These rules use a tiered, risk-based approach. Lower-risk tissues that meet four criteria in 21 CFR 1271.10(a) are regulated "solely under section 361" of the Public Health Service Act. They need no premarket approval, but the establishment must register, screen and test donors, and follow good tissue practice. Tissues that fail any criterion are regulated as drugs, devices and/or biological products and need premarket review.

Approach: I searched FDA's CBER approval records and the Purple Book in our datasets, which show tissue-related approvals but not the tissue rules themselves. The 21 CFR Part 1271 text comes from FDA's tissue pages and its July 2020 HCT/P guidance, which quotes the regulation; the eCFR page itself would not open.

1. Is it an HCT/P at all?

  • Definition: an HCT/P is an article "containing or consisting of human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient" (21 CFR 1271.3(d)).
  • Examples: bone, ligament, skin, dura mater, heart valve, cornea, hematopoietic stem/progenitor cells from peripheral and cord blood, and semen or other reproductive tissue.
  • Not HCT/Ps: vascularized organs for transplantation; whole blood and blood components or derivatives; secreted or extracted products such as milk and collagen (semen excepted); minimally manipulated bone marrow for homologous use; ancillary products; animal tissues; in vitro diagnostics; and blood vessels recovered with an organ for organ transplantation.
  • PRP: FDA treats platelet-rich plasma as a blood product, not an HCT/P.

2. Same surgical procedure exception. An establishment that meets the exception in 21 CFR 1271.15(b) is not subject to Part 1271.

3. Tier 1: regulated solely under section 361. The product must meet all four criteria in 21 CFR 1271.10(a):

  1. It is minimally manipulated. For structural tissue, this means processing that does not alter the tissue's original relevant characteristics for reconstruction, repair or replacement. For cells or nonstructural tissue, it means processing that does not alter their relevant biological characteristics (1271.3(f)).
  2. It is intended for homologous use only, "as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent." Homologous use means the tissue performs the same basic function in the recipient as in the donor (1271.3(c)).
  3. It is not combined with another article, except water, crystalloids, or a sterilizing, preserving or storage agent that raises no new clinical safety concerns.
  4. Either it has no systemic effect and does not depend on living cells' metabolic activity, or it is for autologous use, allogeneic use in a first- or second-degree blood relative, or reproductive use.

FDA classes bone, skin, amniotic membrane and umbilical cord, blood vessel, adipose tissue, cartilage, tendon and ligament as structural tissues. If no information shows that processing is minimal, FDA treats it as "more than minimal manipulation."

Tier 1 obligations (domestic and foreign establishments, 21 CFR 1271.1(b)(1)):

  • Registration and listing: register and list each HCT/P "within five days after beginning operations" (1271.21(a)), using FDA's electronic system, eHCTERS. Waivers from electronic submission are available under §1271.23.
  • Updates: update registration annually in December (1271.21(b)). Ownership, location or US-agent changes need an amendment within 30 calendar days (1271.26).
  • Donor eligibility: screen and test donors, keep written procedures to prevent the spread of communicable disease, and maintain records.
  • Good tissue practice: current good tissue practice requirements apply to tissues recovered after May 25, 2005.
  • What "manufacture" covers: any step in recovery, processing, storage, labeling, packaging or distribution, plus donor screening and testing (1271.3(e)). Contract manufacturers count as establishments.

4. Tier 2: regulated as a drug, device or biologic. Products that fail any 1271.10(a) criterion fall under the FD&C Act and/or section 351 of the PHS Act and need premarket review.

  • Biologics: these need an IND for clinical studies and a BLA to be marketed. They must also meet 21 CFR Parts 210/211 and Parts 600-680.
  • Part 1271 still applies: they remain subject to Part 1271's communicable disease requirements, including registration and listing (1271.1(b)(2)).
  • IND/IDE products: these don't have to register and list until they receive marketing authorization.
  • Enforcement discretion: FDA's period of enforcement discretion for these products ran "through May 31, 2021."

5. Getting a classification decision. The Tissue Reference Group (TRG), with members from CBER and CDRH, gives informal recommendations on how 1271.10(a) applies to a product. Formal designation goes through the Office of Combination Products, as noted in my first answer.

How this shows up in CBER's approval records:

  • A tissue product licensed as a biologic: SYMVESS (acellular tissue engineered vessel-tyod, Humacyte), BLA 125812, approved 12/19/2024 as a vascular conduit for extremity arterial injury [8].
  • Tissue-processing devices cleared by CBER: adipose and lipoaspirate systems such as the LipoGrafter Kit (BK231013, 2024) [9] and Synova WAVE (BK251268, 2025) [10]. Their labeling says the harvested fat is to be reimplanted "without any additional manipulation."
  • Donor screening assays licensed for tissue donors: for example Elecsys HIV Duo, BLA 125778, which is also intended "to screen organ, tissue and cell donors, when donor samples are obtained while the donor's heart is still beating" [11].

Sources:

Q.04